KURA Oct 2024 22.500 call
| Previous close | 4.9000 |
| Open | 4.9000 |
| Bid | 1.3500 |
| Ask | 4.7000 |
| Strike | 22.50 |
| Expiry date | 2024-10-18 |
| Day's range | 4.9000 - 4.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
GlobeNewswireKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 67,950 shares of common stock to six (6) new employees under the
- GuruFocus.com
Kura Oncology Inc (KURA) (Q1 2024) Earnings Call Transcript Highlights: Key Financial and ...
Explore the pivotal updates from Kura Oncology's Q1 2024 earnings call, including financial shifts and significant clinical milestones.
- GlobeNewswire
Kura Oncology Reports First Quarter 2024 Financial Results
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma – – $527 million in cash, cash equivalents and investments provide runway into 2027 – – Management to host webcast and conference call today at 4:3
